Updated:
Galvanize Therapeutics
Galvanize Therapeutics, a San Carlos-based company founded in 2015, develops pulsed electric field systems for therapeutic applications. It has secured $242.5...
Galvanize Therapeutics
Galvanize Therapeutics, a San Carlos-based company founded in 2015, develops pulsed electric field systems for therapeutic applications. It has secured $242.5 million in total funding.
General information
Firm type
other
Location
Region
North America
Country
United States
City
San Carlos
Corporate office
San Carlos, CA, United States
Principals
Doug Godshall
Chairman and CEO
Jonathan Waldstreicher
Founder
Steve Anheier
Chief Regulatory Officer
Kevin Taylor
Deb Sheffield
Chief Regulatory Officer
William S. Krimsky
Chief Medical Officer
Gabe McHugh
Chief Commercial Officer
Seth Harrison
Board Member
Antoine Papiernik
Board Member
Zack Scott
Board Member
David Lewis
Board Member
Laura Francis
Board Member
Sector focus
Frequently asked questions
Who makes investment decisions at Galvanize Therapeutics?
Galvanize is run as an operating company, not an investment fund. CEO Doug Godshall and the leadership team drive strategic decisions, such as product development and regulatory milestones. The board of directors, which includes representatives from major investors like ATP and Sofinnova Partners, oversees governance.
Is Galvanize Therapeutics a family office or a portfolio company?
Galvanize is a medical-device company incubated by ATP (Apple Tree Partners), a venture capital firm. It is not a family office. The firm seeks to commercialize PEF ablation platforms and relies on VC and corporate investors, including Intuitive Surgical and T. Rowe Price, for funding.
What technology does Galvanize Therapeutics develop?
Galvanize specializes in Pulsed Electric Field (PEF) energy for surgical ablation of soft tissue. Its Aliya platform induces regulated cell death without thermal damage, differentiating it from traditional heat-based ablation devices. The latest Aliya EX generator offers expanded treatment volume.
What clinical evidence supports Galvanize's platform?
A November 2025 study showed that Aliya PEF ablation achieved local control of lung tumors in metastatic cancer patients and may trigger an immune response (per the firm, November 2025). The platform also received FDA clearance for surgical ablation in May 2026.
Who are Galvanize Therapeutics' main investors?
Galvanize was created and incubated by ATP. Other investors include Intuitive Surgical, Gilmartin Capital, T. Rowe Price, Sofinnova Partners, Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, and Longaeva.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: